Based on the Synaptogenix Inc stock forecast from 0 analysts, the average analyst target price for Synaptogenix Inc is not available over the next 12 months. Synaptogenix Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Synaptogenix Inc is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Synaptogenix Inc’s stock price was USD 2.16. Synaptogenix Inc’s stock price has changed by -10.37% over the past week, +2.13% over the past month and -54.53% over the last year.
No recent analyst target price found for Synaptogenix Inc
No recent average analyst rating found for Synaptogenix Inc
Company Overview Synaptogenix Inc
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York. Read Less
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanism...Read More
Frequently Asked Questions About Synaptogenix Inc (SNPX) Stock
Stock Target Advisor's fundamental analysis for Synaptogenix Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on SNPX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SNPX's stock to indicate what its average analyst target is.
SNPX stock's Price/Earning ratio is 0.29.
Our analysis grades SNPX stock's Price / Earning ratio at B-. This means that SNPX stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SNPX may be undervalued for its sector.
The last closing price of SNPX's stock was USD 2.16.
The most recent market capitalization for SNPX is USD 3.09M.
Unfortunately we do not have enough analyst data on SNPX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Synaptogenix Inc's stock.
As per our most recent records Synaptogenix Inc has 4 Employees.
Synaptogenix Inc's registered address is 1185 Avenue of the Americas, New York, NY, United States, 10036.
You can get more information about it from Synaptogenix Inc's website at https://www.synaptogen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Synaptogenix Inc (SNPX) Stock
Stock Target Advisor's fundamental analysis for Synaptogenix Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on SNPX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SNPX's stock to indicate what its average analyst target is.
SNPX stock's Price/Earning ratio is 0.29.
Our analysis grades SNPX stock's Price / Earning ratio at B-. This means that SNPX stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SNPX may be undervalued for its sector.
The last closing price of SNPX's stock was USD 2.16.
The most recent market capitalization for SNPX is USD 3.09M.
Unfortunately we do not have enough analyst data on SNPX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Synaptogenix Inc's stock.
As per our most recent records Synaptogenix Inc has 4 Employees.
Synaptogenix Inc's registered address is 1185 Avenue of the Americas, New York, NY, United States, 10036.
You can get more information about it from Synaptogenix Inc's website at https://www.synaptogen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNPX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
